TNFRSF17 (B Cell Maturation Antigen, BCMA) alterations and downstream compensatory pathway activation following BCMA-directed CAR T-cell and bispecific T-cell engagers in multiple myeloma

Multiple myeloma is a cancer of the plasma cells, the white blood cells responsible for making antibodies to fight infection. For years, doctors have struggled to treat patients whose disease returns after initial therapy. In recent years, a new class of treatments has emerged that acts like a guided missile system. These therapies, which include engineered T-cells and bispecific antibodies, are designed to find a specific protein on the surface of cancer cells called BCMA. Once they lock onto this protein, they recruit the patient's own immune system to destroy the cancer. While these treatments often work remarkably well at first, the cancer frequently finds a way to come back. Understanding how the cancer escapes is the key to keeping patients in remission longer.

Scientists have long suspected that when these treatments fail, the cancer cells might simply stop wearing the target protein, effectively becoming invisible to the guided missiles. This idea, known as antigen escape, suggested that the cancer cells were mutating their surface to hide. However, a new study from researchers at Mayo Clinic and other institutions challenges this assumption. By examining the genetic makeup of cancer cells before and after treatment in fifteen patients, the team discovered that the cancer rarely hides by changing its surface. Instead, the cancer cells are often changing their internal wiring to become tougher and harder to kill, even while still wearing the target protein.

The researchers focused on two powerful types of BCMA-targeted therapies: chimeric antigen receptor T-cell therapy, often called CAR T-cell therapy, and T-cell engagers, which are antibodies that link immune cells to cancer cells. They collected bone marrow samples from fifteen patients who had received these treatments and whose disease had progressed. For each patient, they compared the genetic code of the cancer cells before treatment with the code of the cancer cells after the disease returned. They looked specifically for changes in the gene that makes the BCMA protein, as well as changes in the internal pathways that tell the cell to survive and grow.

The findings were surprising. The researchers found that the cancer cells rarely lost or altered the BCMA protein. In the entire group of fifteen patients, only one person showed mutations in the gene responsible for the target protein, and this occurred only after treatment with a T-cell engager. No patient who received CAR T-cell therapy showed any changes to this target gene. Furthermore, the cancer cells did not lose both copies of the gene, which would be necessary to completely stop making the protein. This suggests that for most patients, the cancer cells were still wearing the target, yet the immune system's guided missiles were no longer effective.

Instead of hiding, the cancer cells were strengthening their defenses from the inside. The study revealed that nearly every patient already had genetic changes in their cancer cells before treatment began. These changes affected three major internal signaling pathways that control cell survival and growth. When the treatment was applied, the cancer cells that had these internal changes survived better than the others. As the treatment killed off the weaker cells, the tougher cells with these internal mutations multiplied and took over. In many cases, the treatment itself seemed to select for these resistant clones, making them more common in the bone marrow after the disease returned.

The specific changes found in the surviving cells involved genes that act as brakes or accelerators for cell survival. Some mutations turned off the brakes that normally stop a cell from growing too fast, while others turned on the accelerators that help the cell resist death. The researchers found these changes in pathways known as NF-κB, PI3K-AKT-mTOR, and MAPK. These pathways are like the internal nervous system of the cell, telling it when to live, when to grow, and when to die. By mutating these pathways, the cancer cells raised their threshold for death, making them much harder for the immune system to eliminate, even though the immune system was still successfully finding and grabbing onto the cancer cells.

Another critical finding involved a gene called TP53, which is often described as the guardian of the genome because it helps cells decide to die if they are damaged. The researchers found that some patients acquired new mutations in this gene after treatment. These mutations effectively disabled the cell's ability to commit suicide when attacked. When combined with the other survival mutations, this created a cancer cell that was not only harder to kill but also more aggressive. The study noted that these internal changes were more common in patients who received T-cell engagers compared to those who received CAR T-cell therapy, though both groups showed signs of this resistance mechanism.

The study also looked at whether the cancer cells were simply becoming more numerous or if specific groups of cells were taking over. The researchers found that in many cases, the cancer cells that survived were not just random survivors but were clones that had expanded because they carried these specific survival mutations. This process, known as clonal enrichment, means that the treatment acted as a filter, removing the vulnerable cells and leaving behind a population that was genetically equipped to withstand the attack. This happened in eighty percent of the patients studied, indicating that this is a common way the cancer learns to resist therapy.

The researchers were careful to note that their study had limitations. The group of patients was relatively small, and the types of samples they analyzed varied. They also did not test how these genetic changes affected the proteins inside the cells, so the exact mechanism of how these mutations protect the cell is still being explored. However, the genetic evidence was clear and consistent. The cancer cells were not hiding by removing their target; they were evolving to become more resilient.

This discovery shifts the focus for future treatments. If the cancer is not hiding, then simply trying to find it better may not be enough. The solution may lie in attacking the cancer's internal defenses at the same time as targeting the surface protein. By combining BCMA-targeted therapies with drugs that block the survival pathways the cancer cells rely on, doctors might be able to prevent the cancer from becoming resistant in the first place. The study suggests that the battle against multiple myeloma is not just about finding the enemy, but about understanding how the enemy fortifies its castle walls.

The work provides a clearer picture of why these advanced therapies sometimes stop working. It moves the conversation away from the idea that the cancer simply disappears from the radar and toward a more complex reality where the cancer adapts and hardens. For patients and doctors, this means that monitoring the genetic changes inside the cancer cells could become just as important as monitoring the cancer's size. It also highlights the need for combination therapies that can strike at the cancer's ability to survive, ensuring that when the immune system finds the target, the cell cannot simply shrug off the attack. The path forward involves not just better missiles, but smarter strategies to dismantle the defenses the cancer builds to protect itself.